Clinical Trial Update: Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating dalpiciclib combined with pyrotinib in trastuzumab-sensitive HER2-positive advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Neoplasms

Drugs mentioned

• Dalpiciclib (dalpiciclib)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Breast Neoplasms | Phase 2 | Status: UNKNOWN